Please select the option that best describes you:
Should 1 year of atezolizumab be the standard of care for stage II-IIIA resected PDL1+ NSCLC?
Are the experts convinced by DFS when the OS is immature?
How many in BSC arm went on to receive immunotherapy and was that adequate?
Answer from: Medical Oncologist at Academic Institution
The gold standard endpoint for trials for patients with curable NSCLC has been overall survival. If a therapy delays disease recurrence, but does not impact survival, one could argue that it should not be used in the adjuvant setting and used at the time of recurrence and similar benefits and overal...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Yes – currently adjuvant atezolizumab for 1 year following adjuvant chemotherapy should be discussed and offered as SOC for patients with PD-L1+ stage II-IIIA NSCLC. While OS remains the gold standard by which we evaluate the impact of any form of therapy in the setting of disease treated with...